CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $3.1B, above the global median of $1.15B
- FinancialsLow earnings quality
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.31%
Annual Rate
CNY 0.30Paid semi-annual
Payout Ratio
20.0%Sustainable
Last Ex-Dividend
Jul 13, 2026
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
20.84BCNY3.10B · vs all stocks (USD)
Trailing P/E
87.03xRevenue (TTM)
3.00BCNY446.04M · vs all stocks (USD)
Profit Margin
8.18%Beta
0.5850xvs all stocks
52-Week Change
65.49%vs all stocks
Forward Annual Dividend Yield
0.31%vs all stocks
Market Capitalization
20.84BCNY3.10B · vs all stocks (USD)
Enterprise Value
21.97BCNY3.27B · vs all stocks (USD)
Trailing P/E
87.03xForward P/E
46.34xPrice to Sales (TTM)
7.12xPrice to Book (MRQ)
6.61xEnterprise to Revenue
7.33xEnterprise to EBITDA
43.62xGross Margin
52.43%Profit Margin
8.18%Operating Margin
19.28%Return on Assets (TTM)
4.01%Return on Equity (TTM)
7.51%Revenue (TTM)
3.00BCNY446.04M · vs all stocks (USD)
Revenue per Share (TTM)
14.07CNYUpdated Aug 21, 2026Quarterly Revenue Growth
20.20%Gross Profit (TTM)
1.32BCNY196.53M · vs all stocks (USD)
EBITDA (TTM)
460.15MCNY68.43M · vs all stocks (USD)
Net Income (TTM)
245.26MCNY36.47M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
8.70%Operating Cash Flow (TTM)
386.82MCNY57.52M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
155.47MCNY23.12M · vs all stocks (USD)
Forward Annual Dividend Rate
0.3000CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
0.31%vs all stocks
Trailing Annual Dividend Rate
0.2300CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.24%vs all stocks
Payout Ratio
20.00%Minority Interest (Equity)
49.69MCNYFY2025 · Dec 31, 2025Revenue
2.88BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.52BCNYFY2025 · Dec 31, 2025Gross Profit
1.36BCNYFY2025 · Dec 31, 2025Operating Income
528.73MCNY78.63M · vs all stocks (USD)
Pre-tax Income
275.78MCNYFY2025 · Dec 31, 2025Income Tax Expense
44.13MCNYFY2025 · Dec 31, 2025Net Income
231.65MCNYFY2025 · Dec 31, 2025EBIT
329.58MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
653.37MCNYFY2025 · Dec 31, 2025Research & Development
237.62MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
204.68MCNYFY2025 · Dec 31, 2025Other Operating Expenses
17.96MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
14.11MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
53.80MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.13CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.13CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
212.22MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
212.22MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
231.65MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
8.16MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-189.59MCNYFY2025 · Dec 31, 2025Free Cash Flow
-409.45MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.16BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
231.65MCNYFY2025 · Dec 31, 2025Other Non-cash Items
105.41MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-149.35MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-377.30MCNYFY2025 · Dec 31, 2025Capital Expenditures
-219.86MCNYFY2025 · Dec 31, 2025Net Acquisitions
-56.19MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.46BCNYFY2025 · Dec 31, 2025Sale of Investments
4.54BCNYFY2025 · Dec 31, 2025Other Investing Activity
16.36KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-202.04MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
897.53MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-631.61MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-78.02MCNYFY2025 · Dec 31, 2025Other Financing Charges
-10.89MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
177.00MCNYFY2025 · Dec 31, 2025Shares Outstanding
212.10MSharesUpdated Aug 21, 2026Float Shares
120.46MSharesUpdated Aug 21, 2026% Held by Insiders
44.88%vs all stocks
% Held by Institutions
13.98%vs all stocks
Total Cash (MRQ)
1.65BCNY244.82M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.76CNYUpdated Aug 21, 2026Total Debt (MRQ)
2.35BCNY349.41M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.7234xCurrent Ratio (MRQ)
2.16xBook Value per Share (MRQ)
15.13CNYUpdated Aug 21, 2026Total Assets
6.29BCNY936.02M · vs all stocks (USD)
Total Current Assets
3.79BCNYFY2025 · Dec 31, 2025Total Liabilities
3.11BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.51BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.33BCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.78BCNYFY2025 · Dec 31, 2025Cash
1.52BCNYFY2025 · Dec 31, 2025Cash Equivalents
8.81MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.53BCNYFY2025 · Dec 31, 2025Other Short-term Investments
20.07MCNYFY2025 · Dec 31, 2025Accounts Receivable
646.06MCNYFY2025 · Dec 31, 2025Inventory
1.41BCNYFY2025 · Dec 31, 2025Accounts Payable
476.98MCNYFY2025 · Dec 31, 2025Short-term Debt
991.76MCNYFY2025 · Dec 31, 2025Other Current Liabilities
19.76MCNYFY2025 · Dec 31, 2025Long-term Debt
1.24BCNYFY2025 · Dec 31, 2025Common Stock (Book)
212.10MCNYFY2025 · Dec 31, 2025Retained Earnings
999.00MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.19BCNY473.75M · vs all stocks (USD)
52-Week Low
56.83CNYUpdated Aug 21, 202652-Week High
104.44CNYUpdated Aug 21, 202652-Week Change
65.49%vs all stocks
Beta
0.5850xvs all stocks
50-Day MA
84.79CNYUpdated Aug 21, 2026200-Day MA
76.12CNYUpdated Aug 21, 2026Avg 10-Day Volume
8.19MSharesUpdated Aug 21, 2026Avg 30-Day Volume
6.95MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.15CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.20Receivables vs revenue divergence: 3.52
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.52
Altman Z-Score 5.26: safe zoneNotable
Altman Z-Score: 5.26
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $3.1B, above the global median of $1.15BNotable
Market cap (USD): 3,098,705,286.744Global Median: 1,146,734,693.424
Levered free cash flow is $23.12M, above the global median of $16.24MNotable
Levered free cash flow (USD): 23,119,888.975Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
BioArctic AB
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hybio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Aodong Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MBX Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Walvax Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ABL Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Betta Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rubicon Research Limited
Tier 1ProductionApproval-Gated PipelineRule
Autobio Diagnostics Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Spectra Systems Corporation
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthOperating Income Growing With Multi-Year Revenue Growth
KP Energy Ltd.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthOperating Income Growing With Multi-Year Revenue Growth
Moura Dubeux Engenharia S.A.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthOperating Income Growing With Multi-Year Revenue Growth